An Observational Follow-up Study of Patients Who Experienced Thromboembolic Events in the ENABLE Studies
Phase of Trial: Phase IV
Latest Information Update: 11 Apr 2016
At a glance
- Drugs Eltrombopag (Primary)
- Indications Thrombocytopenia
- Focus Adverse reactions
- Sponsors Novartis
- 07 Apr 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 02 Feb 2016 Planned End Date changed from 1 Sep 2016 to 1 Mar 2016, as reported by ClinicalTrials.gov record.
- 02 Feb 2016 Planned primary completion date changed from 1 Sep 2016 to 1 Mar 2016, as reported by ClinicalTrials.gov record.